Has Peter Attia confirmed he uses testosterone replacement therapy?

Yes. Attia has publicly confirmed TRT use in multiple podcast episodes and in his book *Outlive*. He has described his rationale, monitoring protocol, and side effects openly.

Has Peter Attia confirmed he uses rapamycin?

Yes. Attia has confirmed weekly low-dose rapamycin (sirolimus) use on *The Drive* podcast and in media interviews. He describes it as off-label use for its proposed longevity benefits.

What side effects has Peter Attia publicly described from TRT?

He has discussed hematocrit elevation (requiring monitoring and potential dose adjustment), gonadotropin suppression (with HCG as a countermeasure), and the need for cardiovascular monitoring. These are all well-documented in clinical literature and FDA labeling.

What side effects has Peter Attia publicly described from rapamycin?

He has discussed aphthous ulcers (mouth sores), potential lipid changes, and the nuances of immune modulation at low versus high doses. Each of these is documented in the FDA label and published clinical trials.

Is low-dose rapamycin proven safe for long-term use in healthy adults?

No. While preclinical evidence is promising and small human trials have shown tolerability, no large long-term randomized trial has established the safety or efficacy of chronic low-dose rapamycin in healthy adults for longevity purposes. Current use is entirely off-label.

Side Effects Peter Attia Publicly Discussed (and What They Match in the Clinical Literature)

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Why Peter Attia's Public Record Matters

Few physicians have disclosed their own pharmacologic longevity regimen with as much clinical specificity as Peter Attia. Through his podcast (The Drive), his 2023 book Outlive, and long-form interviews, Attia has described his personal use of testosterone replacement therapy and weekly low-dose rapamycin (sirolimus). He has framed these disclosures as teaching opportunities, walking listeners through lab values, dosing decisions, and the side effects he watches for.

That transparency makes his case unusually useful for clinical education. Rather than speculating about a celebrity's drug use, we can compare his self-reported experience directly to the published safety data.

At a glance

TRT status: Confirmed. Attia has stated on multiple podcast episodes and in Outlive that he uses exogenous testosterone.
Rapamycin status: Confirmed. He has described a weekly low-dose sirolimus protocol publicly on The Drive and in interviews.
Key side effects discussed: Hematocrit elevation (TRT), lipid changes (rapamycin), mouth sores/aphthous ulcers (rapamycin), and immune monitoring considerations (rapamycin).
Monitoring approach: Attia has publicly emphasized frequent blood work, including CBC, metabolic panels, lipid panels, and sirolimus trough levels.

Testosterone Replacement Therapy: What Attia Has Said and What the Data Shows

Confirmed Use and Rationale

Attia has publicly stated that he began TRT after identifying suboptimal testosterone levels through routine lab work. In Outlive and on The Drive, he described his decision as driven by symptoms (fatigue, reduced recovery capacity) combined with laboratory confirmation. He has not disclosed his exact dose publicly, though he has discussed targeting physiologic levels rather than supraphysiologic ranges.

Hematocrit Elevation

One side effect Attia has repeatedly flagged in public discussions is the rise in hematocrit that accompanies exogenous testosterone. This is among the most common adverse effects listed in the FDA prescribing information for testosterone products. The mechanism is straightforward: testosterone stimulates erythropoietin production in the kidney, which drives red blood cell production.

In clinical trials, hematocrit elevation above 54% occurred in roughly 5 to 15 percent of men on TRT, depending on the formulation and dose. The Endocrine Society's 2018 clinical practice guidelines recommend checking hematocrit at baseline, at 3 to 6 months, and then annually, with dose reduction or temporary cessation if hematocrit exceeds 54%.

Attia has discussed managing this through regular phlebotomy monitoring and dose titration. His public commentary aligns precisely with guideline-recommended practice.

Fertility and Gonadotropin Suppression

Attia has also acknowledged publicly that exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing or eliminating endogenous sperm production. The FDA label for testosterone cypionate lists oligospermia and azoospermia as known effects. Attia has noted this is a significant consideration for men of reproductive age and has discussed concurrent use of HCG (human chorionic gonadotropin) to maintain testicular function, a strategy supported by published clinical data though not FDA-approved for this specific indication.

Cardiovascular Monitoring

Attia has spoken publicly about monitoring cardiovascular markers closely while on TRT. The relationship between TRT and cardiovascular risk has been debated for over a decade. The TRAVERSE trial, published in the New England Journal of Medicine in 2023, was the first large randomized trial powered for cardiovascular endpoints. It found that testosterone was noninferior to placebo for major adverse cardiovascular events in men with hypogonadism and preexisting or high risk for cardiovascular disease, though a signal for increased atrial fibrillation, acute kidney injury, and pulmonary embolism was noted.

The HealthRX Medical Team take: Attia's public approach to TRT monitoring, frequent hematocrit checks, lipid panels, cardiovascular imaging, and dose adjustments, represents what evidence-based TRT management should look like. The side effects he describes publicly are the exact ones the clinical literature identifies as most common. His transparency about these effects serves as a corrective to the common misconception that TRT is risk-free.

Rapamycin (Sirolimus): What Attia Has Said and What the Data Shows

Confirmed Use and Protocol

Attia has confirmed on The Drive and in media interviews that he takes rapamycin (sirolimus) at a low weekly dose for its proposed geroprotective effects. He has described this as an off-label use, distinct from the drug's FDA-approved indications for organ transplant rejection prophylaxis and lymphangioleiomyomatosis. His publicly stated rationale centers on the mTOR inhibition pathway and the strong preclinical evidence showing lifespan extension across multiple species.

Aphthous Ulcers (Mouth Sores)

Attia has publicly discussed experiencing mouth sores while on rapamycin. This is one of the best-documented side effects of mTOR inhibitors. In a phase 2a trial by Mannick et al. (2014) published in Science Translational Medicine, which tested the mTOR inhibitor everolimus in elderly volunteers, mouth ulcers were the most commonly reported adverse event, occurring in approximately 15 to 25 percent of participants even at low doses.

The FDA label for sirolimus lists stomatitis and oral ulceration across all approved-dose populations. The mechanism is thought to involve local inhibition of mucosal cell proliferation and possibly altered local immune responses.

The HealthRX Medical Team Side-Effect Mapping Framework

The table below maps each side effect Peter Attia has publicly described to its corresponding entry in FDA labeling and peer-reviewed trial evidence. This framework helps readers distinguish between effects that are well-characterized in published data and those that remain under active investigation.

| Side Effect Discussed | Drug | FDA Label Match | Trial Incidence | Attia's Stated Management | |---|---|---|---|---| | Hematocrit elevation | TRT | Yes (boxed monitoring) | 5-15% of TRT users | Regular CBC, dose titration | | Gonadotropin suppression | TRT | Yes (oligospermia listed) | Expected in all users | HCG co-administration discussed | | Aphthous ulcers | Rapamycin | Yes (stomatitis) | 15-25% (Mannick 2014) | Dose holidays discussed | | Lipid perturbations | Rapamycin | Yes (hyperlipidemia) | 40-60% at transplant doses | Monitoring, lower dosing | | Immune modulation | Rapamycin | Yes (immunosuppression) | Dose-dependent | Trough level monitoring |

Lipid Changes

Attia has publicly acknowledged that rapamycin can alter lipid profiles. This is well documented in the transplant literature, where hypercholesterolemia and hypertriglyceridemia occur in 40 to 60 percent of patients on standard immunosuppressive doses. At the lower doses used in the longevity community, the effect appears attenuated but not absent.

Attia has discussed monitoring his lipid panels closely and has noted that any lipid changes at his dose were modest. The published low-dose data remains limited. A 2018 pilot study in healthy older adults found that intermittent rapamycin dosing produced less lipid disruption than continuous dosing, supporting the rationale behind weekly rather than daily administration.

Immune Function Considerations

Perhaps the most nuanced side effect Attia has discussed publicly is the paradoxical relationship between rapamycin dose and immune function. At high transplant-level doses, rapamycin is a potent immunosuppressant. At low intermittent doses, preclinical data and the Mannick et al. trial suggest it may actually enhance certain immune responses, particularly vaccine responses in elderly populations.

Attia has spoken about this distinction carefully, noting that he monitors sirolimus trough levels to remain well below immunosuppressive thresholds. He has also discussed timing doses around periods when immune competence is especially important.

The HealthRX Medical Team take: The distinction between immunosuppressive and immunostimulatory doses of rapamycin is real but the clinical boundaries remain poorly defined in humans. Attia's public framing is scientifically accurate, but readers should understand that no long-term randomized trial has established the safety of chronic low-dose rapamycin in healthy adults. The side effects he reports (mouth sores, lipid shifts) are consistent with mTOR inhibition even at low doses, and they signal that the drug is pharmacologically active. Absence of side effects at a given dose does not confirm therapeutic benefit.

What Attia Has Not Publicly Reported

It is worth noting what Attia has not described experiencing publicly. He has not reported significant mood changes on TRT (reported by 3 to 10 percent of users in clinical trials), acne or skin changes (reported in up to 8 percent), or sleep apnea worsening (a known TRT risk, especially at higher doses). He has not reported wound healing delays on rapamycin, an effect documented in the surgical literature at standard doses.

This does not mean these effects are absent in his case. It means only that he has not discussed them in public forums. We note these omissions to give readers a complete picture of the documented side-effect profiles of both drugs.

Frequently asked questions

›